Search research articles
Contact Us
Filters
Showing results (121-130 of 168) with videos related to
Page
of 17
Sort By:
Cancer
|
August 27, 2019
Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study
Karen M Freund, Jennifer S Haas, Stephenie C Lemon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Andrea Eisen, Mark R Somerfield, Melissa K Accordino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2017
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update
Catherine Van Poznak, Mark R Somerfield, William E Barlow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
<i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR<sup>+</sup>) Breast Cancer
Joshua Z Drago, Luigi Formisano, Dejan Juric, et al.
JAMA Oncology
|
November 6, 2015
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
Chau Dang, Hao Guo, Julie Najita, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 7, 2022
Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer
Joseph A Greer, Beverly Moy, Areej El-Jawahri, et al.
Breast Cancer Research and Treatment
|
March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
José Baselga, Serafin M Morales, Ahmad Awada, et al.
Molecular Cancer Research : MCR
|
February 18, 2018
AR Expression in Breast Cancer CTCs Associates with Bone Metastases
Nicola Aceto, Aditya Bardia, Ben S Wittner, et al.
The Lancet. Oncology
|
December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
Paul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Cristina Saura, Judit Matito, Mafalda Oliveira, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 168) with videos related to
Sort By:
Page
of 17
Cancer
|
August 27, 2019
Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study
Karen M Freund, Jennifer S Haas, Stephenie C Lemon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Andrea Eisen, Mark R Somerfield, Melissa K Accordino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2017
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update
Catherine Van Poznak, Mark R Somerfield, William E Barlow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
<i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR<sup>+</sup>) Breast Cancer
Joshua Z Drago, Luigi Formisano, Dejan Juric, et al.
JAMA Oncology
|
November 6, 2015
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
Chau Dang, Hao Guo, Julie Najita, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 7, 2022
Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer
Joseph A Greer, Beverly Moy, Areej El-Jawahri, et al.
Breast Cancer Research and Treatment
|
March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
José Baselga, Serafin M Morales, Ahmad Awada, et al.
Molecular Cancer Research : MCR
|
February 18, 2018
AR Expression in Breast Cancer CTCs Associates with Bone Metastases
Nicola Aceto, Aditya Bardia, Ben S Wittner, et al.
The Lancet. Oncology
|
December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
Paul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Cristina Saura, Judit Matito, Mafalda Oliveira, et al.
Page
of 17